PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

NCT04745949 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Cyclophosphamide
DRUG: Doxorubicin
BIOLOGICAL: Nivolumab
DRUG: Prednisone
OTHER: Quality-of-Life Assessment
BIOLOGICAL: Rituximab

Sponsor

M.D. Anderson Cancer Center